Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Appalaches Capital, LLC Jake Keys | “We had the opportunity to invest in shares of McKesson Corporation (MCK) during a bout of general market apathy towards defensive businesses. McKesson is one of the 'Big Three' drug distributors in the U.S. As a group, they control over 90% of all drug distribution. Centralized drug distributors are important due to the complexity of the pharmaceutical supply chain, and they are necessary for connecting two highly fragmented ends of the market. Even if sourcing drugs was relatively straightforward, that is, if every drug was branded and sold by one manufacturer, pharmacies would still need to coordinate the delivery of hundreds of separate SKUs per day. Manufacturers would also need to coordinate their own delivery logistics, of which the handling is highly regulated under federal law. You could easily imagine an unwieldy complicated system where a pharmacy has dozens of trucks stopping by at all hours of the day. Instead, distributors make life easy by consolidating inventory and managing the entire change-of-control process. The opportunity for McKesson is a rapidly changing backdrop in the generic pharmaceutical market. The last decade has been challenging for the company due to weakness amongst generic manufacturers, and the litigation overhang as a consequence of the opioid crisis. Today, however, there is strong reason to believe that stabilization is coming to the generic market and the risks from opioid litigation have been largely resolved. Under their traditional distribution model, McKesson acquires and distributes branded and generic drugs to pharmacies, doctors offices, and hospitals. Within branded drugs, McKesson is typically compensated under a fee-for-service arrangement, which leads to fixed gross profits on inflated prices. In this case, McKesson is working with one manufacturer and many pharmacies, resulting in limited negotiating power on the buy side and on the sell margin. Generic drugs on the other hand, are manufactured by many different parties, resulting in stronger negotiating leverage for McKesson on the buy margin. Gross margins on generics are consequently upwards of 10x higher than branded drugs. Since 2016, the generic drug market has experienced prolonged price depreciation after a dearth of new generic offerings came to market in the prior decade, which stimulated competition and price wars amongst manufacturers. Drug distributors were consequently unable to capture as much margin on generics, which is where a significant portion of their gross profits are made. There are many reasons to believe that stabilization is occurring and is likely to be sustainable for the foreseeable future. The most obvious of which is that nearly $100 billion worth of branded drugs are expected to go off patent in 2028 alone. This upcoming patent cliff acts as a tailwind for generic price stability, as well as a mix shift margin opportunity for distributors. Instead of having to fight tooth and nail to gain volume in existing products, manufacturers will have the opportunity to focus on new generic launches and alleviate the constant undercutting in existing products. This tailwind is sustainable as well. With a typical patent life being twenty years, the drugs coming off patent today were first released around 2006. This marked a low point in development for the industry, and the approval of New Molecular Entities (NMEs) began a strong trend upward lasting until today. This suggests that the opportunity set for new generic formulations could grow until at least 2045 before seeing any significant drought. This was not the case during the last major patent cliff in 2016, due to a dramatic increase in NMEs in 1996 but less approvals in the years following. Capacity within the generic drug manufacturing industry has also exited or has been retooled for other purposes. Major players like Teva and Sandoz have rationalized their portfolios to exit traditional oral solids and shifted their capacity towards more complex deliveries, like inhalers and injectables. All else equal, less supply should lead to further improvements in price stability. Just like high prices, low prices inevitably work themselves out in the free market. Biologics have been coming into vogue over the last couple of decades, and so many of McKesson's largest opportunities are in this category. As the name implies, biologics are derived from living organisms rather than static formulas of chemicals. These typically require more delicate storage and handling, for example, Pfizer states their COVID-19 vaccine is required to be stored between -90°C and -60°C. Biologics, with their more complicated handling requirements, allow McKesson to provide more services and consequently collect higher fees. Now that many of these are also going off patent as biosimilars (the analog for generics in this category), McKesson has a clear line of sight towards sustainable, higher margin volume growth here. The pharmaceutical industry as a whole possesses very high barriers to entry that stem from the sheer scale of these operations. The gross margin on the entire business in 2025 was just 3.7%, driven in part by fee for service arrangements but also by a generally low toll collected from the value chain. This commitment to non-extractive pricing results in a market that cannot support other competitors. Given that performing this service cheaply and with high levels of availability is what drives value for customers and suppliers, it only makes sense that the industry would remain consolidated. There is little incentive to require a new competitor because there is clear value already being provided. Even in new launches that have sought a direct-to-consumer model, such as GLP-1s, the pharma industry has still largely relied on the big three for managing the logistics. High margins can be admirable, but even more admirable is a company taking a small spread and turning it into high profitability through well managed efficiency – McKesson's return on invested capital is over 50%, which is driven primarily by their high utilization and turnover of their capital base. In terms of a variant view, my estimates for the coming year do not differ too far from the average analyst. However, based on the current valuation of around 16x forward free cash flow, the collective market does not seem to think that this growth is very persistent. With the attractive generic and biosimilar pipeline, I believe gross profits could grow at a high single digit rate for the foreseeable future which will provide a further uplift to margins. With continued repurchases shareholders should stand to do well from here.” | NEUTRAL | Q2 2026 Jun 30, 2026 | View Pitch |
Alluvium Global Fund Stuart Pearce, Alexis Delloye | “McKesson, the drug distributor (up 6.3%), reported a very good set of results and management raised its guidance for the year ending March 2026. Strong performance in the pharmaceutical division was largely driven by GLP1 drugs, and recent acquisitions have performed well. The impressive results led to a marginal increase to our valuation. Both HCA and McKesson account for more than 5% of the Fund. With the share prices of these businesses being at circa 40% premiums to our valuations, and applying subjective considerations, these businesses were deemed to best qualify for the required selling, though both remain large positions. BSD Analysis: McKesson sits at the least glamorous but most powerful choke point in U.S. healthcare: drug distribution. Scale is the moat here — pharmacies and manufacturers can complain, but they can't bypass McKesson without breaking the system. Margins are thin by design, yet cash flow is massive because volume and velocity do the work. Specialty pharma and oncology distribution add higher-quality growth on top of the core utility. Regulatory noise never goes away, but it usually reinforces incumbents rather than disrupts them. Capital allocation has improved dramatically, with buybacks doing real work. This is not a healthcare innovation story. It's healthcare plumbing with monopoly-like characteristics. McKesson compounds because the system depends on it functioning.” | BULL | Q4 2025 Jan 23, 2026 | View Pitch |
Greenfield Investment Management Erin Greenfield | “McKesson – This is a pharmaceutical distribution company, operating mainly in the United States. I followed their industry for many years. I first bought the stock for US$144 in the spring of 2018 when many investors worried the company would be permanently damaged by liabilities stemming from the opioid crisis in the United States. We later bought the stock for US$205 when Greenfield started managing money in September 2021, representing roughly 10 times earnings. The stock has climbed steadily to US$824 today, which works out to roughly 20 times earnings. We have trimmed the position size but continue to own shares today. I see the investment similar to a royalty on Americans taking more pharmaceuticals over time. BSD Analysis: McKesson sits at the least glamorous but most powerful choke point in U.S. healthcare: drug distribution. Scale is the moat — pharmacies and manufacturers can complain, but they can't bypass McKesson without breaking the system. Margins are thin by design, yet cash flow is massive because volume and velocity do the work. Specialty pharma and oncology distribution add higher-quality growth on top of the utility core. Regulatory noise never disappears, but it usually entrenches incumbents rather than disrupts them. Capital allocation has improved meaningfully, with buybacks doing real work. This is not a healthcare innovation story. It's healthcare plumbing with monopoly-like characteristics. McKesson compounds because the system depends on it functioning.” | BULL | Q4 2025 Jan 5, 2026 | View Pitch |
Latitude Global Fund Freddie Lait | “We started to see this opportunity in 2022, when we first invested in McKesson, a drug distribution company, and we now own its peer Cencora too. Both stocks produced returns of roughly 50% last year, driven by strong fundamental value growth of around 20% and some re-rating on top. The distribution model has proven its strong resilience, with companies having meaningfully reduced their dependence on drug pricing in the past decade. They are in effect a toll road on the US healthcare system and the opposite of economic rent-seeking businesses, creating huge value for the system while only earning a very small fraction of the industry profit pool. While growing profits, they have also invested heavily in both technology and infrastructure, embedding their market positions at the centre of the US healthcare system. BSD Analysis: McKesson is entering the 2026 fiscal year in a position of strength, recently raising its adjusted earnings guidance to reflect robust prescription volumes and expansion in high-margin specialty services. The company's strategic shift toward becoming a diversified healthcare services leader is underscored by its growing footprint in oncology and biopharma services, which are delivering double-digit operating profit growth. Revenue for the current year is projected to exceed 400 billion dollars, supported by the integration of strategic acquisitions like Florida Cancer Specialists and a leadership position in the US Oncology Network. Management is also prioritizing the digitization of its platform, investing in AI-driven prescription technology to improve patient adherence and streamline distribution efficiency. With a strong track record of outperforming analyst expectations and a focus on high-growth therapeutic areas, McKesson remains a premier pick in the healthcare distribution sector.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
The Bristol Gate U.S. Equity Strategy Achilleas Taxildaris | “Healthcare services company McKesson benefitted from its core US pharmaceutical distribution businesses in speciality and high growth areas like GLP-1 medication. It also demonstrated strategic portfolio management through the acquisition of PRISM Vision Holdings, and the divestiture of its Canadian retail businesses (Rexall and Well.ca) while continuing to focus on efficiency and cost control. BSD Analysis: McKesson is an unassailable, low-margin pharmaceutical distribution giant whose stock is a conviction bet on the non-cyclical, predictable demand for healthcare. The core moat is its indispensable role as the largest pharmaceutical distributor in North America, securing a massive scale advantage and high barriers to entry. The company's specialty is its focus on higher-margin oncology solutions and its role in drug and medical supply management for specialty practices. While operating margins are thin, the sheer volume and stability of its distribution network ensure predictable, compounding cash flow. McKesson is a defensive core holding that benefits from the non-discretionary growth of the global pharmaceutical market.” | BULL | Q2 2025 Jul 21, 2025 | View Pitch |
Alluvium Global Fund Stuart Pearce, Alexis Delloye | “McKesson reported robust financial results, narrowed its guidance upward, and expanded its portfolio through the strategic acquisition of PRISM Vision. Although the stock currently trades at a premium to the fund's conservative valuation model, the manager remains comfortable holding the position due to the firm's consistent execution and long-term EPS growth potential.” | BULL | Q1 2025 Mar 1, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
